首页> 美国卫生研究院文献>BMC Medical Genomics >From big data analysis to personalized medicine for all: challenges and opportunities
【2h】

From big data analysis to personalized medicine for all: challenges and opportunities

机译:从大数据分析到全民个性化医学:挑战与机遇

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent advances in high-throughput technologies have led to the emergence of systems biology as a holistic science to achieve more precise modeling of complex diseases. Many predict the emergence of personalized medicine in the near future. We are, however, moving from two-tiered health systems to a two-tiered personalized medicine. Omics facilities are restricted to affluent regions, and personalized medicine is likely to widen the growing gap in health systems between high and low-income countries. This is mirrored by an increasing lag between our ability to generate and analyze big data. Several bottlenecks slow-down the transition from conventional to personalized medicine: generation of cost-effective high-throughput data; hybrid education and multidisciplinary teams; data storage and processing; data integration and interpretation; and individual and global economic relevance. This review provides an update of important developments in the analysis of big data and forward strategies to accelerate the global transition to personalized medicine.
机译:高通量技术的最新进展已导致系统生物学作为一种整体科学的出现,以实现对复杂疾病的更精确建模。许多人预测在不久的将来会出现个性化医学。但是,我们正在从两级保健系统过渡到两级个性化药品。 Omics设施仅限于富裕地区,个性化医学可能会扩大高收入国家和低收入国家之间在卫生系统方面日益扩大的差距。我们生成和分析大数据的能力之间的差距越来越大,这反映了这一点。几个瓶颈阻碍了从传统医学到个性化医学的过渡:生成具有成本效益的高通量数据;混合教育和多学科团队;数据存储和处理;数据整合和解释;以及个人和全球经济相关性。这篇综述提供了对大数据分析的重要进展的最新动态,以及加快全球向个性化医学过渡的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号